Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
...unchanged
Pharma launches up 80.4% to €689 million, led by ALTUVIIIO, Nexviazyme, Rezurock, and Sarclisa
Vaccines sales -4.8% due to COVID-19 sales in 2023
Opella (former Sanofi Consumer Healthcare) up 9.6%, driven by the Qunol acquisition
Research and...
Zur Pressemeldung auf www.sanofi.com